Xtandi’s Success A Double-Edged Sword
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas/Medivation prostate cancer drug is the latest focus of drug pricing criticism in the news but it doesn’t seem likely that NIH will grant open licenses on the drug’s patent under its “march-in” authority, as legislators and advocacy groups request.